See the DrugPatentWatch profile for albumin

Based on the information available, there is some evidence to suggest that albumin may influence paclitaxel uptake in cancer cells.

Paclitaxel is a chemotherapy drug used to treat various types of cancer, including ovarian, breast, and non-small cell lung cancer. It is often administered in combination with albumin, a protein found in blood plasma, to form a complex known as nab-paclitaxel (Abraxane).

Studies have shown that the albumin-paclitaxel complex can increase the drug's solubility, allowing for higher doses to be administered and potentially improving its efficacy. Additionally, the albumin component of the complex may facilitate the uptake of paclitaxel by cancer cells through receptor-mediated endocytosis, a process by which cells absorb molecules from their external environment.

One study published in the Journal of Controlled Release found that the albumin-paclitaxel complex was taken up by cancer cells at a higher rate than paclitaxel alone, suggesting that albumin may enhance the drug's uptake and activity.

In summary, while more research is needed to fully understand the relationship between albumin and paclitaxel uptake in cancer cells, current evidence suggests that the albumin-paclitaxel complex may increase the drug's solubility and facilitate its uptake by cancer cells.

Sources:

1. [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/abraxane)
2. Journal of Controlled Release. (2013). Mechanisms of cellular uptake and intracellular trafficking of nanoparticle albumin-bound paclitaxel. <https://doi.org/10.1016/j.jconrel.2013.02.011>